You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
CRUK will invest £40 million over the next five years to support the alliance, while US partners will invest $20 million to support research projects and infrastructure.
The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
The platform, which its developers said is well suited to point-of-care testing, uses fluorescent polymers to distinguish between samples from cases and controls.
The model aims to uncover stroke patients at high, medium, or low risk of cerebral amyloid angiopathy, which is linked to additional strokes or dementia.